Prothena Corporation

Prothena Corporation Equity

The The Equity of Prothena Corporation (PRTA) as of Oct 5, 2026 is 280.47 M USD. In the previous year, The Equity was 486.93 M USD — a change of -42.40% (lower).

Equity

280.47 MUSD

YoY

-42.40%

Last updated:

In 2026, Prothena Corporation's equity was 280.47 M USD, a -42.40% increase from the 486.93 M USD equity in the previous year.

The Prothena Corporation Equity history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Equity
Date
Equity
Jan 1, 2018
323.00 M USD
Jan 1, 2019
272.92 M USD
Jan 1, 2020
184.01 M USD
Jan 1, 2021
466.04 M USD
Jan 1, 2022
622.04 M USD
Jan 1, 2023
561.37 M USD
Jan 1, 2024
486.93 M USD
Jan 1, 2025
280.47 M USD
The Prothena Corporation Equity history
YEAREquityYoY
280.47 MUSD-42.40%
486.93 MUSD-13.26%
561.37 MUSD-9.75%
622.04 MUSD+33.47%
466.04 MUSD+153.28%
184.01 MUSD-32.58%
272.92 MUSD-15.50%
323.00 MUSD-20.68%
407.19 MUSD+11.44%
365.40 MUSD+1.31%
360.67 MUSD+24.42%
289.89 MUSD—
Access this data via the Eulerpool API

Prothena Corporation Stock analysis

What does Prothena Corporation do? Prothena Corporation PLC is a biopharmaceutical company based in Dublin, Ireland, specializing in the development of therapies for protein diseases. The company was spun off from Elan Corporation's research department in 2012 and has been listed on NASDAQ since 2014. Prothena's business model is based on the discovery and development of novel therapeutic approaches for neurodegenerative diseases and cancer caused by misfolded proteins. The company leverages its expertise in protein biochemistry and physics to identify targeted drug candidates that can modulate specific protein structures and their functions. Prothena's key focus areas include researching antibodies against amyloid-beta plaques, which accumulate in the brain in Alzheimer's disease, and developing molecules that can inhibit the disease-causing protein alpha-synuclein in Parkinson's patients. Additionally, the company is working on therapies for ATTR (amyloidosis) and AL amyloidosis. A major success for Prothena was the development of NEOD001, a humanized antibody that targets the amyloid fibril protein (AL) deposited in AL amyloidosis. The drug demonstrated significant efficacy in clinical trials and improved patients' quality of life. Prothena licensed NEOD001 to Pfizer in 2017. Another important product from Prothena is PRX002, a monoclonal antibody specifically targeting the alpha-synuclein protein and inhibiting its spread in the brain. PRX002 is currently undergoing clinical trials for the treatment of Parkinson's patients and is considered a promising medication. Prothena collaborates closely with research partners and other pharmaceutical companies such as Roche/Genentech and Celgene to advance their research activities and the development of new therapeutics. The company has strong regulatory expertise and aims to obtain approvals for new therapies to provide improved quality of life for patients with rare or serious diseases. Overall, Prothena is a leading company in the field of protein biochemistry and the development of innovative therapies for protein diseases. With a strong research pipeline and a wide range of product candidates, the company has the potential to improve the lives of millions of people suffering from serious illnesses. Prothena Corporation is one of the most popular companies on Eulerpool.

Equity Details

Analyzing Prothena Corporation's Equity

Prothena Corporation's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Prothena Corporation's equity is essential for assessing its financial health, stability, and value to shareholders.

Year-to-Year Comparison

Evaluating Prothena Corporation's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.

Impact on Investments

Prothena Corporation's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.

Interpreting Equity Fluctuations

Fluctuations in Prothena Corporation’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.

Frequently Asked Questions about Prothena Corporation stock

The Equity of Prothena Corporation is 280.47 M USD in 2026.

The Equity of Prothena Corporation changed from 486.93 M USD to 280.47 M USD, representing a -42.40% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of The Equity Prothena Corporation since 2006 – with annual values, charts, and detailed analysis.

The Equity's USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track The Equity's Prothena Corporation historically and in real time.

Access this data via the Eulerpool API

Balance Sheet — Prothena Corporation

All Key Metrics — Prothena Corporation